Envestnet Asset Management Inc. Has $11.18 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Envestnet Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 36.9% during the 4th quarter, Holdings Channel reports. The fund owned 90,742 shares of the specialty pharmaceutical company’s stock after buying an additional 24,443 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Jazz Pharmaceuticals were worth $11,175,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth $25,000. CoreFirst Bank & Trust bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $28,000. Allianz SE acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth $29,000. Jones Financial Companies Lllp lifted its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares in the last quarter. Finally, UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Piper Sandler reiterated an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Royal Bank of Canada reduced their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Stock Up 1.2 %

NASDAQ:JAZZ opened at $102.78 on Friday. The firm has a market capitalization of $6.24 billion, a price-to-earnings ratio of 14.48, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The stock’s 50 day moving average price is $128.14 and its two-hundred day moving average price is $122.36. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Activity

In related news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the sale, the chief executive officer now owns 440,307 shares in the company, valued at $54,487,991.25. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 in the last quarter. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.